# A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors

> **NCT05830045** · PHASE1 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QLP2117

## Key facts

- **NCT ID:** NCT05830045
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-19
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830045, "A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05830045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*